Glaucoma Clinical Trial
Official title:
Parameters for Disease Progression in Chinese Patients With Normal Tension Glaucoma
To obtain demographic and baseline ophthalmic parameters (such as Intraocular Pressure profiles, disc morphological characteristics, central corneal thickness, peripapillary retinal nerve fibre layer thickness and its serial changes, visual field changes, severity of any medical associations—e.g. hypertension, migraine, strokes, silent cerebral infarcts) with non-invasive measurements, in Chinese Patients with Normal Tension Glaucoma
This is a multi-centered non-interventional descriptive study. The Declaration of Helsinki
is followed. All procedures will be conducted in accordance with the GCP guidelines.
About 100 Consecutive NTG glaucoma patients will be included in this study. NTG is defined
as:
1. Six median untreated intraocular pressure consistently less than 21 mm Hg, with no more
than 1 reading = 23 mmHg or 24 mmHg, and with no single measurement greater than 24 mm
Hg,
2. Open drainage angles on gonioscopy,
3. Typical optic disc damage with glaucomatous cupping and loss of neuroretinal rim,
4. Absence of any secondary cause for a glaucomatous optic neuropathy (trauma, steroids,
uveitis),
5. Glaucomatous visual field defect compatible with glaucomatous optic neuropathy.
Age and sex-matched normal control subjects and age, sex, severity-matched POAG control
subjects will be recruited.
Randomization not required as this will be a non-interventional descriptive study.
A complete baseline ophthalmic assessment will be performed with Snellen visual acuity (VA),
Best-corrected VA, intraocular pressure (IOP) measurements, slit lamp examination,
gonioscopy, disc assessment and dilated fundal examination.
These measurements were performed at recruitment and then at 3,6,9,12 months after the
intervention. The details of some of these measurements were as follows.
All IOP was measured with Goldmann applanation tonometry. The median of 5 readings were
taken. Gonioscopy was carried out first using a Goldmann 2-mirror gonioscope. The
examination was carried out at the lowest level of illumination that permitted a view of the
angle and at high magnification (×16 to ×25). A 1-mm light beam was reduced to a very narrow
slit, and was offset horizontally for assessing superior and inferior angles and vertically
for nasal and temporal angles. Care was taken to avoid light falling on the pupil during
gonioscopy. Slight tilting to gain a view over the convexity of the iris was permitted, but
further manipulation of the lens or redirection of gaze was avoided because of the
possibility of exerting pressure on the cornea and artificially widening the angle. The
drainage angle was graded according to Shaffer's convention in each quadrant. The average
angle width was calculated by adding the Shaffer grade in each quadrant and dividing by 4.
Indentation gonioscopy using a Posner lens was also used to detect PAS, and the number of
clock hours of PAS was recorded. All gonioscopy was performed by a single investigator for
standardization.
The vertical CDR was taken to be the longest vertical cup diameter divided by the longest
vertical disc diameter. Estimates were made to the nearest 0.05. The vertical disc diameter
was examined. All features of a glaucomatous optic neuropathy were noted.
All subjects underwent static automated white-on-white threshold perimetry (program 24- 2,
SITA standard, model 750, Humphrey Instruments, Dublin, CA), and the first reliable VF was
used in our analysis. The global indices mean deviation (MD), and pattern standard deviation
(PSD) were documented for all cases. After finding the proportion of VF that is reliable,
the VF was then scored using the tested scoring algorithm developed for the Advanced
Glaucoma Intervention Study (AGIS).
Minimal criteria for glaucomatous VF defect were as follows: glaucoma hemifield test outside
normal limits, pattern standard deviation with a P value of <5%, or a cluster of ≥3 points
in the pattern deviation plot in a single hemifield (superior or inferior) with P value of
<5%, one of which must have a P value of <1%. Any one of the preceding criteria, if
repeatable, was considered sufficient evidence of a glaucomatous VF defect.
Subjects will be verified by diurnal tension curve, which was recorded no more than one year
before inclusion in the present study.
Systemic haemodynamics Systolic, diastolic, and mean blood pressures (SBP, DBP, MAP) were
measured on the upper arm by an automated oscillometric device. Pulse rate (PR) and blood
oxygenation was automatically recorded from a finger pulse oximetric device (HP-CMS patient
monitor, Hewlett Packard, Palo Alto, CA, USA).
Measurement of intraocular pressure (IOP) A Median of 3 readings for each subject with
Goldmann applanation tonometer was used for each measurement of intraocular pressure.
Fundus Photography and Optical Coherence Tomography (OCT) A baseline fundus photo will be
performed for all participants. A baseline OCT for retinal nerve fiber layer thickness and
optic nerve head parameters will be determined. Serial changes of these parameters will be
correlated to VF indices.
Dynamic Contour Tonometry (DCT) and Ocular Response Analyzer (ORA) will also be performed on
these subjects.
A history of the following systemic conditions was recorded: systemic hypertension (HT),
hypotension, ischemic heart disease (IHD), arrhythmia, diabetes mellitus (DM),
hypercholesterolemia, cerebral vascular accidents (CVA), migraine, obstructive sleep apnea
(OSA), sensorineural hearing loss and Raynaud's phenomenon. All diagnoses were obtained from
the history and confirmed by the clinical management system of the Hong Kong Hospital
Authority, which is a computerized database connecting all public hospitals and clinics in
Hong Kong.
Systemic use of statins, beta-blockers, angiotensin-converting-enzyme-inhibitors (ACEI),
calcium-channel-blockers, aspirin and diuretics was also noted.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |